Vioxx Fallout Still Hangs Heavy Over FDA Advisory Committees

Four years after Merck removed Vioxx from the market, FDA's advisory committee members are still wary of making a similar mistake. At a July 29 Arthritis Advisory Committee meeting for Roche's Actemra (tocilizumab), panel members expressed concern that elevated LDL levels could portend increased risk of CV events